Dr. Wei joined Baiyu in June 2019.He was appointed to lead the Research and Development of innovative drugs as the General Manager of the Innovative R&D center. Dr. Wei obtained his PhD in Organic Chemistry from the University of Wisconsin-Madison. He published nearly 200 new drug invention patents, led 1 first-in-class drug NDA and six first-in-class drugs to clinical stage. He won the honors of Sichuan Tianfu Qingcheng expert and Sichuan overseas high-level talent.
One of the most important functions of DNA-PK is to participate in the DNA damage repair response. DNA-PK inhibitors enhance the effect of chemoradiotherapy by inhibiting the DNA damage repair pathway. BY101298 can be used in combination with chemoradiotherapy to enhance the efficacy of chemoradiotherapy. BY101298 is the first highly selective DNA-PK inhibitor in China independently developed by BAIYU, which has good safety profile and significantly enhances the anti-tumor efficacy of chemoradiotherapy.
One of the most important functions of DNA-PK is to participate in the DNA damage repair response. DNA-PK inhibitors enhance the effect of chemoradiotherapy by inhibiting the DNA damage repair pathway. BY101298 can be used in combination with chemoradiotherapy to enhance the efficacy of chemoradiotherapy. BY101298 is the first highly selective DNA-PK inhibitor in China independently developed by BAIYU, which has good safety profile and significantly enhances the anti-tumor efficacy of chemoradiotherapy.
We look forward to building flexible, collaborative and inclusive forms of cooperation with the global partners to promote the early and successful launch of innovative drugs. Welcome to contact:bd@baiyu.cn
Chengdu Baiyu Pharmaceutical Co., Ltd. All rights reserved 《互联网药品信息服务资格证》 证书编号:(川)-非经营性-2018-0009 备案证号:蜀ICP备16017620号